LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

15.72 5.01

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

14.97

Максимум

16.46

Ключови измерители
By Trading Economics
Приходи	11M -61M
Продажби	7.9M 46M
EPS	-0.7
Марж на печалбата	-132.36
Служители	270
EBITDA	6.6M -57M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+134.91% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	56M 1.2B
Предишно отваряне	10.71
Предишно затваряне	15.72

Настроения в новините

By Acuity

26%

74%

60 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.11.2025 г., 21:36 ч. UTC

Печалби

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

9.11.2025 г., 21:22 ч. UTC

Печалби

Australia's ANZ Bank Posts 10% Drop in Annual Profit

10.11.2025 г., 00:00 ч. UTC

Пазарно говорене

India Inflation Poised to Hit New Low -- Market Talk

9.11.2025 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

9.11.2025 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

9.11.2025 г., 21:05 ч. UTC

Печалби

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

9.11.2025 г., 21:04 ч. UTC

Печалби

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

9.11.2025 г., 21:03 ч. UTC

Печалби

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

9.11.2025 г., 20:49 ч. UTC

Печалби

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

9.11.2025 г., 20:49 ч. UTC

Печалби

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

9.11.2025 г., 20:45 ч. UTC

Печалби

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

9.11.2025 г., 20:45 ч. UTC

Печалби

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

9.11.2025 г., 20:42 ч. UTC

Печалби

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

9.11.2025 г., 20:42 ч. UTC

Печалби

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

9.11.2025 г., 20:41 ч. UTC

Печалби

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

9.11.2025 г., 20:41 ч. UTC

Печалби

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

9.11.2025 г., 20:39 ч. UTC

Печалби

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

9.11.2025 г., 20:39 ч. UTC

Печалби

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

9.11.2025 г., 20:38 ч. UTC

Печалби

ANZ Keeps Dividend at A$0.83 >ANZ.AU

9.11.2025 г., 20:38 ч. UTC

Печалби

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

9.11.2025 г., 20:38 ч. UTC

Печалби

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

8.11.2025 г., 13:10 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8.11.2025 г., 03:50 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8.11.2025 г., 03:41 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8.11.2025 г., 03:07 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7.11.2025 г., 22:36 ч. UTC

Печалби

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7.11.2025 г., 22:22 ч. UTC

Печалби

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q Rev $2.95B >CSU.T

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q Net $210M >CSU.T

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q EPS $9.89 >CSU.T

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

134.91% нагоре

12-месечна прогноза

Среден 35.33 USD 134.91%

Висок 56 USD

Нисък 22 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

60 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.